Yixin Zhong Selected Research

Therapeutics

1/2023	Magnetic Response Combined with Bioactive Ion Therapy: A RONS-Scavenging Theranostic Nanoplatform for Thrombolysis and Renal Ischemia-Reperfusion Injury.
3/2022	Mitochondrial Glutathione Depletion Nanoshuttles for Oxygen-Irrelevant Free Radicals Generation: A Cascaded Hierarchical Targeting and Theranostic Strategy Against Hypoxic Tumor.
2/2022	Biomimetic nanoprobe-augmented triple therapy with photothermal, sonodynamic and checkpoint blockade inhibits tumor growth and metastasis.
10/2021	Tumor-self-targeted "thermoferroptosis-sensitization" magnetic nanodroplets for multimodal imaging-guided tumor-specific therapy.
9/2021	Multifunctional nanozyme for multimodal imaging-guided enhanced sonodynamic therapy by regulating the tumor microenvironment.
1/2021	Combination Nanotherapeutics for Dry Eye Disease Treatment in a Rabbit Model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yixin Zhong Research Topics

Disease

6	Thrombosis (Thrombus) 01/2023 - 12/2017
6	Neoplasms (Cancer) 03/2022 - 08/2018
2	Breast Neoplasms (Breast Cancer) 02/2022 - 01/2019
2	Neoplasm Metastasis (Metastasis) 02/2022 - 09/2021
1	Reperfusion Injury 01/2023
1	Fibrosis (Cirrhosis) 01/2023
1	Hepatocellular Carcinoma (Hepatoma) 12/2022
1	Liver Neoplasms (Liver Cancer) 12/2022
1	Hemorrhage 04/2022
1	Hyperthermia 10/2021
1	Vascular Tissue Neoplasms 10/2021
1	Hypoxia (Hypoxemia) 09/2021
1	Inflammation (Inflammations) 01/2021
1	Dry Eye Syndromes (Dry Eye Syndrome) 01/2021
1	Atherosclerotic Plaque (Atheroma) 03/2019
1	Residual Neoplasm 01/2019
1	Body Weight (Weight, Body) 04/2014
1	Coronary Disease (Coronary Heart Disease) 04/2014
1	Hypertension (High Blood Pressure) 04/2014
1	Stroke (Strokes) 04/2014
1	Parkinson Disease (Parkinson's Disease) 04/2014
1	Orthostatic Hypotension (Postural Hypotension) 04/2014

Drug/Important Bio-Agent (IBA)

4	Oxygen (Dioxygen)IBA 01/2023 - 08/2018
3	perflubron (L 1913)FDA Link 01/2021 - 08/2018
2	FibrinIBA 04/2022 - 01/2019
2	Glutathione (Reduced Glutathione)IBA 03/2022 - 09/2021
2	cysteinyl-arginyl-glutamyl-lysyl-alanylIBA 01/2022 - 01/2019
2	Liposomes (Liposome)IBA 01/2021 - 01/2019
1	NitrogenIBA 01/2023
1	Ketotifen (Ketotifene)FDA Link 04/2022
1	IronIBA 03/2022
1	Free RadicalsIBA 03/2022
1	Immune Checkpoint InhibitorsIBA 02/2022
1	ferric oxide (iron oxide)IBA 02/2022
1	hematoporphyrin monomethyl etherIBA 02/2022
1	mahuang-tangIBA 10/2021
1	Therapeutic UsesIBA 09/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2021
1	CytokinesIBA 01/2021
1	tetrandrineIBA 01/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021
1	ApolipoproteinsIBA 03/2019
1	Apolipoproteins E (ApoE)IBA 03/2019
1	CholesterolIBA 03/2019
1	Coloring Agents (Dyes)IBA 01/2019
1	IntegrinsIBA 01/2019
1	LigandsIBA 01/2019
1	polydopamineIBA 01/2019
1	Peptides (Polypeptides)IBA 01/2019
1	IodidesIBA 01/2019
1	Indicators and Reagents (Reagents)IBA 01/2019
1	P-SelectinIBA 01/2019
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 08/2018
1	Contrast MediaIBA 12/2017
1	Antihypertensive Agents (Antihypertensives)IBA 04/2014
1	hydroxide ionIBA 04/2014

Therapy/Procedure

6	Therapeutics 01/2023 - 01/2021
5	Precision Medicine 01/2023 - 12/2017
2	Immunotherapy 12/2022 - 02/2022
2	Photothermal Therapy 01/2019 - 08/2018
1	Drug Therapy (Chemotherapy) 12/2022
1	Photochemotherapy (Photodynamic Therapy) 08/2018
1	Phototherapy (Light Therapy) 08/2018